High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention

Journal of Cardiovascular Medicine

Volumn 16, Issue 3, 2015, Pages 213-219

  Jo, Sang Ho ^a   Hahn, Joo Yong ^b   Lee, Sung Yun ^c   Kim, Hyun Joong ^d   Song, Young Bin ^b   Choi, Jin Ho ^b   Choi, Seung Hyuk ^b   Lee, Sang Hoon ^b   Gwon, Hyeon Cheol ^b  

^a Hallym University Sacred Heart Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

Author keywords

Contrast media; Prevention; Renal failure; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CONTRAST MEDIUM; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART FAILURE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RENAL REPLACEMENT THERAPY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; CHEMICALLY INDUCED; CLINICAL TRIAL; KIDNEY DISEASES; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ATORVASTATIN CALCIUM; CONTRAST MEDIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84925881093     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000157     Document Type: Article

References (24)

1. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354:379-386.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
3. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
4. Jo SH. N-acetylcysteine for prevention of contrast-induced nephropathy: a narrative review. Korean Circ J 2011;41:695-702.
5. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-1785.
6. Kim YR, Park JH, Lee HJ, Pyun WB, Park SH. The effect of doubling the statin dose on pro-inflammatory cytokine in patients with triple-vessel coronary artery disease. Korean Circ J 2012;42:595-599.
7. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di SG. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of M-ocardial Damage during Angioplasty) study. Circulation 2004;110:674-678.
8. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-2163.
9. Sim DS, Jeong MH, Cho KH, et al. Effect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarction. Korean Circ J 2013;43:100-109.
10. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial: a randomized controlled study. Am Heart J 2008;155:499-508.
11. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012;7:e34450.
12. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol 2011;153:323-325.
13. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Statins and contrastinduced nephropathy: issues requiring further investigation. Int J Cardiol 2011;151:364.
14. Hahn JY, Kim HJ, Choi YJ, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2011;162:1026-1033.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285.
17. Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010;105:288-292.
18. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrastinduced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
19. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 2011;124:1250-1259.
20. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011;27:851-858.
21. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a metaanalysis. Int J Cardiol 2011;151:348-353.
22. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention [from the ARMYDA-CIN (atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy) trial]. Am J Cardiol 2011;108:1-7.
23. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early highdose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014;63:71-79.
24. Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 2012;122:195-202.